Epstein-Barr virus (EBV) is a major factor causing nasopharyngeal
carcinoma and its load has many implications in screening, early
detection as well as monitoring treatment response. The study aimed
to determine the changes in plasma EBV DNA load level in
nasopharyngeal carcinoma (NPC) patients treated with concurrent
chemoradiotherapy at Thai Nguyen National Hospital. A crosssectional descriptive study was on 57 NPC patients which are
measured for plasma EBV DNA load and treated with concurrent
chemoradiotherapy from January 2022 to December 2023. The
average age was 52.4; the male/female ratio was 2.2/1; 54.4% of
patients were stage T3 or T4; 14.0% of patients had no lymph node
metastasis; 63.2% of patients were stage III; the rate of EBV positive
before treatment: 37.7% (0-8,960,000 copies/ml). Plasma EBV DNA
was significantly increased in N0 patients and tend to be high in T3,
T4 stage; stage III, IVA and elderly patients. After treatment, 95.3%
of patients were EBV negative. High plasma EBV DNA load
appeared to be associated with complete response to treatment. Thus,
plasma EBV DNA load is related to both clinical characteristics and
treatment outcomes of nasopharyngeal carcinoma.